238 related articles for article (PubMed ID: 30012322)
1. Lipoprotein(a) and Cardiovascular Risk Prediction Among Women.
Cook NR; Mora S; Ridker PM
J Am Coll Cardiol; 2018 Jul; 72(3):287-296. PubMed ID: 30012322
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of B-type Natriuretic Peptides to Predict Cardiovascular Events in Women (from the Women's Health Study).
Everett BM; Ridker PM; Cook NR; Pradhan AD
Am J Cardiol; 2015 Aug; 116(4):532-7. PubMed ID: 26081066
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S
Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events.
Suk Danik J; Rifai N; Buring JE; Ridker PM
J Am Coll Cardiol; 2008 Jul; 52(2):124-31. PubMed ID: 18598891
[TBL] [Abstract][Full Text] [Related]
5. Baseline and on-statin treatment lipoprotein(a) levels for predicting cardiovascular events in patients with familial hypercholesterolemia.
Cao YX; Jin JL; Guo YL; Sun D; Liu HH; Wu NQ; Xu RX; Zhu CG; Liu G; Dong Q; Sun J; Li JJ
Atherosclerosis; 2019 Dec; 291():27-33. PubMed ID: 31683090
[TBL] [Abstract][Full Text] [Related]
6. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
[TBL] [Abstract][Full Text] [Related]
7. Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial.
Ridker PM; MacFadyen JG; Wolfert RL; Koenig W
Clin Chem; 2012 May; 58(5):877-86. PubMed ID: 22419750
[TBL] [Abstract][Full Text] [Related]
8. Blood lipids and lipoproteins in relation to incidence and mortality risks for CVD and cancer in the prospective EPIC-Heidelberg cohort.
Katzke VA; Sookthai D; Johnson T; Kühn T; Kaaks R
BMC Med; 2017 Dec; 15(1):218. PubMed ID: 29254484
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Disease, Mortality Risk, and Healthcare Costs by Lipoprotein(a) Levels According to Low-density Lipoprotein Cholesterol Levels in Older High-risk Adults.
Zhao Y; Delaney JA; Quek RG; Gardin JM; Hirsch CH; Gandra SR; Wong ND
Clin Cardiol; 2016 Jul; 39(7):413-20. PubMed ID: 27177347
[TBL] [Abstract][Full Text] [Related]
10. Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities.
Fras Z
Anatol J Cardiol; 2020 Jan; 23(2):60-69. PubMed ID: 32011323
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a) levels and risk of abdominal aortic aneurysm in the Women's Health Initiative.
Chou EL; Pettinger M; Haring B; Mell MW; Hlatky MA; Wactawski-Wende J; Allison MA; Wild RA; Shadyab AH; Wallace RB; Snetselaar LG; Eagleton MJ; Conrad MF; Liu S
J Vasc Surg; 2021 Apr; 73(4):1245-1252.e3. PubMed ID: 32882349
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options.
Anagnostis P; Karras S; Lambrinoudaki I; Stevenson JC; Goulis DG
Int J Clin Pract; 2016 Dec; 70(12):967-977. PubMed ID: 28032426
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of lipoprotein-associated phospholipase A₂ for cardiovascular disease prediction in a multiethnic cohort of women.
Cook NR; Paynter NP; Manson JE; Martin LW; Robinson JG; Wassertheil-Smoller S; Ridker PM
Clin Chem; 2012 Sep; 58(9):1352-63. PubMed ID: 22859728
[TBL] [Abstract][Full Text] [Related]
14. Statin-associated incident diabetes: a literature review.
Park ZH; Juska A; Dyakov D; Patel RV
Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study.
Madsen CM; Kamstrup PR; Langsted A; Varbo A; Nordestgaard BG
Arterioscler Thromb Vasc Biol; 2020 Jan; 40(1):255-266. PubMed ID: 31578080
[TBL] [Abstract][Full Text] [Related]
16. The re-emergence of lipoprotein(a) in a broader clinical arena.
Tsimikas S
Prog Cardiovasc Dis; 2016; 59(2):135-144. PubMed ID: 27497506
[TBL] [Abstract][Full Text] [Related]
17. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study.
Willeit P; Kiechl S; Kronenberg F; Witztum JL; Santer P; Mayr M; Xu Q; Mayr A; Willeit J; Tsimikas S
J Am Coll Cardiol; 2014 Sep; 64(9):851-60. PubMed ID: 25169167
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular disease and Lp(a) in the adult population and in the elderly: the Brisighella study.
Nascetti S; D'Addato S; Pascarelli N; Sangiorgi Z; Grippo MC; Gaddi A
Riv Eur Sci Med Farmacol; 1996; 18(5-6):205-12. PubMed ID: 9177623
[TBL] [Abstract][Full Text] [Related]
19. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
